enVVeno Medical Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update

Author's Avatar
Mar 28, 2022
  • Ended the Year With $55 Million in Cash Expected To Fund Operations Through the End of 2024 Including Release of Topline Pivotal Trial Data
  • Nine (9) VenoValve Surgeries Successfully Completed and 16 Clinical Sites Currently Active in Ongoing SAVVE U.S Pivotal Trial
  • Continued Advancement in Development of Second Device for the Treatment of Venous Disease Expected To Be Unveiled in Mid-2022